Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.62), $0.28 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $46.26 million versus the consensus estimate of $41.83 million.

“We delivered a record-setting quarter in terms of robust sales, improving gross margin and modest use of cash,” said Kim Blickenstaff, president and chief executive officer. “We’ll be working to build upon this momentum by continuing to scale our business into a leading global diabetes management organization, while advancing our product pipeline and furthering our mission to improve the lives of people with diabetes.”

GUIDANCE:

Tandem Diabetes sees FY2018 revenue of $160-165 million, versus the consensus of $155.42 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.